Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer
Howard L. Kaufman(Rutgers, The State University of New Jersey), Neil L. Berinstein(Sanofi (Canada)), Chris Garett(Moffitt Cancer Center), Danielle Salha(Sanofi (Canada)), Judy Caterini(Sanofi (Canada)), Walter J. Urba(Providence Portland Medical Center), Al B. Benson(Northwestern University), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Seunghee Kim‐Schulze(Icahn School of Medicine at Mount Sinai), John L. Marshall(Vince Lombardi Cancer Clinic), Richard Dalfen(St Mary's Hospital Centre), Robert M. Conry(University of Alabama), C. Cripps(Canadian Partnership Against Cancer), W. Heim(Hematology and Oncology Associates of Northeastern Pennsylvania), Thorsten U. Vogel(Sanofi (Canada)), Margaret von Mehren(Temple University Health System), Deepti Singh(University of Chicago), Maria Cecília Zorat Yu(Sanofi (Canada)), Mark DeBenedette(Sanofi (Canada)), Ileana Elias, Malcolm J. Moore(University Health Network)
Cited by 121
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k